Typ I Interferon receptor deficient mice for analysing immunological diseases

<strong>Bckground</strong><br>

Interferons play a vital role in the natural response on viral infection. In particular, type I interferon (IFN-I) is the focus of interest in the development of new therapeutic approaches for example in the fields of immunology, tumor diseases, multiple sclerosis and sepsis. </p> <strong>Technology</strong><br> Two novel transgenic mice have been developed, the IFNAR knock-out mouse (IFNARKO) and the conditional IFNAR mouse (IFNARCOND), both congenic on the C57BL/6 background, the mouse type from which most of the tumors used in tumor models are isolated. The IFNARKO mouse carries an ubiquitous deletion of the interferon type I receptor (IFNAR) allowing investigations into the role of IFNAR in every tissue and every stage of development. The conditional IFNAR-mouse allows the potential IFNAR inactivation by an adequate stimulus in a specific tissue or cell type. By this, the function of the IFN-I system can be investigated in its spatial and temporal dimensions for the first time by targeted time- and/or site-controlled IFNAR inactivation.<br><br> <p><strong>Benefits</strong> <ul> <li>Both mice are congenic (IFNARKO :20x crossed back; IFNARCOND :10x crossed back) on the C57BL/6 background (tumor mice)</li> <li>IFNARCOND based on Dupont’s Cre/loxP technology</li> <li> Big variety of transgenic mice regulating expression of the recombinase Cre in different cell types or tissues allows production of almost any kind of IFNAR deletion types.</li> </ul> <p><strong>IP Rights</strong><br> German Utility Models<br> IFNAR-KO No. 202004019129.6<br> IFNAR-COND No. 202004019128.8 </p> <p><strong>Origin</strong><br> Breeding took place at the Paul-Ehrlich-Institute (PEI) following GLP standard.</p> <p> </p>

Weitere Informationen: PDF

ipal GmbH
Tel.: +49 (0)30/2125-4820

Ansprechpartner
Dr. Dirk Dantz